

1-(4-Methoxyphenyl)-3,3-bis(methylsulfanyl)-  
2-phenylprop-2-en-1-oneK. Palani,<sup>a</sup> M. N. Ponnuswamy,<sup>a\*</sup>  
P. Jaisankar<sup>b</sup> and P. C.  
Srinivasan<sup>b</sup><sup>a</sup>Department of Crystallography and Biophysics,  
University of Madras, Guindy Campus, Chennai  
600 025, India, and <sup>b</sup>Department of Organic  
Chemistry, University of Madras, Guindy  
Campus, Chennai 600 025, IndiaCorrespondence e-mail:  
mnp2004@yahoo.com

## Key indicators


Single-crystal X-ray study  
 $T = 293$  K  
Mean  $\sigma(\text{C}-\text{C}) = 0.004$  Å  
 $R$  factor = 0.058  
 $wR$  factor = 0.172  
Data-to-parameter ratio = 22.5For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.

In the title compound,  $\text{C}_{18}\text{H}_{18}\text{O}_2\text{S}_2$ , there are two independent and conformationally similar molecules in the asymmetric unit. In one of the molecules, the dihedral angle between the two aromatic rings is  $77.1(2)^\circ$ , and in the other it is  $78.2(2)^\circ$ . The two independent molecules are linked by a  $\text{C}-\text{H}\cdots\pi$  interaction.

Received 26 March 2007  
Accepted 30 March 2007


## Comment

Chalcone and its derivatives are natural and synthetic compounds belonging to the flavonoid family. They possess a broad spectrum of biological activities, including antibacterial, antihelmintic, amoebicidal, anti-ulcer, antiviral, insecticidal, antiprotzoal, anticancer, cytotoxic and immunosuppressive activities (Dimmock *et al.*, 1999). Chalcone derivatives were also reported to inhibit the destruction of the myelin sheath in the central nervous system of multiple sclerosis patients and were thus useful in controlling the progressive nature of the disease (Edwards *et al.*, 1989). Chalcone derivatives are notable for their excellent blue light transmittance and good crystallizability (Fichou *et al.*, 1988; Kitaoka *et al.*, 1990; Zhao *et al.*, 2000). Sulfur-containing compounds act as simple diuretics (Crawford and Kennedy, 1959). Against this background, the crystal structure of the title compound, (I), has been determined and the results are presented here.



The asymmetric unit of (I) contains two independent and conformationally similar molecules, *A* and *B* (Fig. 1). Bond lengths and angles of these two molecules agree with each other, and the  $\text{C}-\text{S}$  distances agree well with those observed in a similar structure (Woźniak *et al.*, 2006). The dihedral angle between the two aromatic rings is  $77.1(2)^\circ$  in molecule *A* and  $78.2(2)^\circ$  in *B*. In both molecules the methoxy group is almost coplanar with the attached ring.

A weak  $\text{C}-\text{H}\cdots\text{S}$  intramolecular interaction is observed in both *A* and *B*. The two independent molecules are linked *via* a



**Figure 1**  
The asymmetric unit of (I), showing 30% probability displacement ellipsoids. The dashed line indicates a C—H... $\pi$  interaction.

C—H... $\pi$  interaction involving the C9B—C14B benzene ring (Table 1).

## Experimental

Benzyl *p*-anisyl ketone (5.0 mmol) in dry THF (20 ml) and carbon disulfide (5.1 mmol) in dry THF (10 ml) were added slowly to a stirred suspension of 50% NaH (0.24 g, 10 mmol) in dry THF (4 ml) under a nitrogen atmosphere at 273 K. The reaction mixture was stirred at 273–278 K for 10 min. Methyl iodide (13.0 mmol) in dry THF (10 ml) was then added and the reaction mixture was stirred at 273–278 K for 2 h. The solution was then treated with saturated aqueous ammonium chloride solution (50 ml) and the layers were separated. The aqueous layer was extracted with chloroform (4  $\times$  15 ml), and the combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give an oil. This was crystallized from chloroform and hexane (3:7) to give a yellow crystalline solid (yield 82%).

### Crystal data

C <sub>18</sub> H <sub>18</sub> O <sub>2</sub> S <sub>2</sub>	$V = 3387.2 (19) \text{ \AA}^3$
$M_r = 330.44$	$Z = 8$
Monoclinic, $P2_1/a$	Mo $K\alpha$ radiation
$a = 16.471 (3) \text{ \AA}$	$\mu = 0.32 \text{ mm}^{-1}$
$b = 9.879 (4) \text{ \AA}$	$T = 293 (2) \text{ K}$
$c = 22.065 (8) \text{ \AA}$	$0.24 \times 0.22 \times 0.19 \text{ mm}$
$\beta = 109.362 (17)^\circ$	

### Data collection

Enraf–Nonius CAD-4 diffractometer	4621 reflections with $I > 2\sigma(I)$
Absorption correction: none	$R_{\text{int}} = 0.030$
9240 measured reflections	3 standard reflections
8931 independent reflections	frequency: 60 min
	intensity decay: none

### Refinement

$R[F^2 > 2\sigma(F^2)] = 0.058$	397 parameters
$wR(F^2) = 0.172$	H-atom parameters constrained
$S = 1.02$	$\Delta\rho_{\text{max}} = 0.43 \text{ e \AA}^{-3}$
8931 reflections	$\Delta\rho_{\text{min}} = -0.24 \text{ e \AA}^{-3}$

**Table 1**

Hydrogen-bond geometry ( $\text{\AA}, ^\circ$ ).

Cg1 is the centroid of the C9B—C14B benzene ring.

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
C3A—H3A...S1A	0.93	2.85	3.218 (4)	105
C3B—H3B...S1B	0.93	2.82	3.212 (4)	106
C13A—H13A...Cg1	0.93	2.78	3.701 (3)	171

H atoms were placed in idealized positions and allowed to ride on their parent atoms, with C—H = 0.93 or 0.96  $\text{\AA}$  and  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$  or  $1.5U_{\text{eq}}(\text{methyl C})$ .

Data collection: *CAD-4 EXPRESS* (Enraf–Nonius, 1994); cell refinement: *CAD-4 EXPRESS*; data reduction: *XCAD4* (Harms & Wocadlo, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ZORTEP* (Zsolnai, 1997); software used to prepare material for publication: *SHELXL97* and *PLATON* (Spek, 2003).

KP thanks the University Grants Commission (UGC) Herbal Science programme for financial support under the 'University with Potential for Excellence' scheme. The UGC and the Department of Science and Technology (DST) are gratefully acknowledged for financial support to the Department of Crystallography and Biophysics under the UGC-SAP and DST-FIST programmes.

## References

- Crawford, J. D. & Kennedy, G. C. (1959). *Nature (London)*, **183**, 891–892.
- Dimmock, J. R., Elias, D. W., Beazely, M. A. & Kandepu, N. M. (1999). *Curr. Med. Chem.* **6**, 1125–1149.
- Edwards, M. L., Sunkara, S. P. & Stermerick, D. M. (1989). US Patent No. 4 863 968.
- Enraf–Nonius (1994). *CAD-4 EXPRESS*. Enraf–Nonius, Delft, The Netherlands.
- Fichou, D., Watanabe, T., Takeda, T., Miyata, S., Goto, Y. & Nakayama, M. (1988). *Jpn J. Appl. Phys.* **27**, L429–L430.
- Harms, K. & Wocadlo, S. (1995). *XCAD4*. University of Marburg, Germany.
- Kitaoka, Y., Sasaki, T., Nakai, S., Yokotani, A., Goto, Y. & Nakayama, M. (1990). *Appl. Phys. Lett.* **56**, 2074–2076.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Woźniak, D., Szymańska, A., Sikorski, A., Konitz, A. & Lis, T. (2006). *Acta Cryst. E* **62**, o295–o297.
- Zhao, B., Lu, W.-Q., Zhou, Z.-H. & Wu, Y. (2000). *J. Mater. Chem.* **10**, 1513–1517.
- Zsolnai, L. (1997). *ZORTEP*. University of Heidelberg, Germany.